Invivyd announces general alignment with FDA on EUAs for antibodies of COVID-19

Invivyd announced general alignment with the U.S. Food and Drug Administration, FDA, on an expedient, repeatable immunobridging pathway to future potential emergency use authorizations, EUAs, for serial, novel monoclonal antibodies for the prevention and treatment of symptomatic COVID-19. Coupled with Invivyd’s proprietary mAb technology platform and engineering capabilities, this pathway provides the company with the opportunity to rapidly, efficiently, and durably deliver high value medicines that prevent and treat symptomatic COVID-19 in vulnerable populations.